All Episodes
|
65
|
John Marchica

Episode 65: Our Take, August 12, 2019

Aug 12, 2019

Episode Summary

In today’s Our Take read-in, “The FDA announced Tuesday that Novartis submitted the drug application for Zolgensma, the company’s novel gene therapy treatment for spinal muscular atrophy, with manipulated data. The FDA said it is assessing the matter and ‘remains confident’ that the gene therapy will continue to be available to patients.”

Episode Notes

In today’s Our Take read-in, “The FDA announced Tuesday that Novartis submitted the drug application for Zolgensma, the company’s novel gene therapy treatment for spinal muscular atrophy, with manipulated data. The FDA said it is assessing the matter and ‘remains confident’ that the gene therapy will continue to be available to patients.” To sign up for the weekly email brief, click here.

Other briefs include:

  • Allscripts Healthcare Solutions reached a tentative $145 million settlement agreement with the Department of Justice.
  • CMS has agreed to reimburse any FDA-approved chimeric antigen receptor (CAR) T-cell therapies.
  • SSM Health is introducing an individual health plan in the St. Louis market this fall.
  • Provention Bio’s teplizumab received the FDA’s Breakthrough Therapy Designation.
  • New York City launched NYC Care, a program that offers health care to uninsured residents.
  • CVS has expanded its CarePass program to participating CVS pharmacies throughout the U.S.
  • Walgreens customers can soon get select prescription Bausch Health dermatology products for a flat rate.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 213: Health Care's Affordability Crisis Is Getting Worse w/ Larry Levitt, CEO-Elect & EVP, KFF
Podcast 212: Are We Measuring Health Care Quality All Wrong? w/ Dr. Rachel Werner, Professor of Medicine, UPenn
Podcast 211: The State of Value-Based Health Care w/ John Marchica, Darwin Research Group
Podcast 210: Why Health Care Reform Keeps Falling Short w/ Dr. Elliott Fisher, Dartmouth Institute
Podcast 209: Inside the Rural Health Transformation Program w/ Dr. Tim Ferris, InterSystems
Podcast 208: The Affordability Crisis Behind Value-Based Care w/ Dr. Michael Chernew, Harvard
Podcast 207: What’s Holding Back Value-Based Care? w/ Don Calcagno, Founder, ValuesEdge
Podcast 206: Why Membership Medicine Could Save Primary Care w/ Larry Kutscher, CEO, MDVIP

Recommended Content

Browse Library
INsights
August 17, 2026

Darwin's Our Take 8.17.26: Trump tries again to revise federal childhood vaccination recommendations

Read More
INsights
August 10, 2026

Darwin's Our Take 8.10.26: Summa Health names new CEO to lead next phase of HATCo's health assurance vision

Read More
INsights
August 3, 2026

Darwin's Our Take 8.3.26: Loss of ‘enhanced’ ACA subsidies hits IDNs harder than expected

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.